Vitamin D receptor agonists in the treatment of autoimmune diseases: Selective targeting of myeloid but not plasmacytoid dendritic cells

Journal of Bone and Mineral Research

Volumn 22, Issue SUPPL. 2, 2007, Pages

  Penna, Giuseppe ^a   Amuchastegui, Susana ^a   Laverny, Gilles ^a   Adorini, Luciano ^a  

^a BioXell SpA   (Italy)

Author keywords

1,25 Dihydroxyvitamin D3; Autoimmune diseases; Myeloid dendritic cells; Plasmacytoid dendritic cells; Tolerogenic dendritic cells

Indexed keywords

UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR AGONIST;

AUTOIMMUNE DISEASE; BONE MARROW CELL; CD4+ CD25+ T LYMPHOCYTE; CONFERENCE PAPER; DENDRITIC CELL; DRUG EFFICACY; DRUG TARGETING; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PLASMACYTOID DENDRITIC CELL; T LYMPHOCYTE;

EID: 39749149619     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.07s217     Document Type: Conference Paper

References (42)

1. 1 Adorini L 2001 Selective immunointervention in autoimmune diseases: Lessons from multiple sclerosis. J Chemother 13: 219–234.
2. 2 Hackstein H, Thomson AW 2004 Dendritic cells: Emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 4: 24–34.
3. 3 Adorini L, Giarratana N, Penna G 2004 Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol 16: 127–134.
4. 4 Penna G, Adorini L 2000 1,25‐dihydroxyvitamin D3 inhibits differentiation, maturation, activation and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 164: 2405–2411.
5. 5 Piemonti L, Monti P, Sironi M, Fraticelli P, Leone BE, Dal Cin E, Allavena P, Di Carlo V 2000 Vitamin D3 affects differentiation, maturation, and function of human monocyte‐derived dendritic cells. J Immunol 164: 4443–4451.
6. 6 Griffin MD, Lutz WH, Phan VA, Bachman LA, McKean DJ, Kumar R 2000 Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun 270: 701–708.
7. 7 Berer A, Stockl J, Majdic O, Wagner T, Kollars M, Lechner K, Geissler K, Oehler L 2000 1,25‐Dihydroxyvitamin D(3) inhibits dendritic cell differentiation and maturation in vitro. Exp Hematol 28: 575–583.
8. 8 Canning MO, Grotenhuis K, de Wit H, Ruwhof C, Drexhage HA 2001 1‐alpha,25‐Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. Eur J Endocrinol 145: 351–357.
9. 9 van Halteren AG, van Etten E, de Jong EC, Bouillon R, Roep BO, Mathieu C 2002 Redirection of human autoreactive T‐cells upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3). Diabetes 51: 2119–2125.
10. 10 Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, Sanvito F, Doglioni C, Adorini L 2006 Treatment of experimental autoimmune prostatitis in non‐obese diabetic mice by the vitamin D receptor agonist elocalcitol. J Immunol 177: 8504–8511.
11. 11 Penna G, Roncari A, Amuchastegui S, Daniel KC, Berti E, Colonna M, Adorini L 2005 Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25‐dihydroxyvitamin D3. Blood 106: 3490–3497.
12. 12 Adorini L 2005 Intervention in autoimmunity: The potential of vitamin D receptor agonists. Cell Immunol 233: 115–124.
13. 13 van Etten E, Mathieu C 2005 Immunoregulation by 1,25‐dihydroxyvitamin D3: Basic concepts. J Steroid Biochem Mol Biol 97: 93–101.
14. 14 Campbell MJ, Adorini L 2006 The vitamin D receptor as a therapeutic target. Expert Opin Ther Targets 10: 735–748.
15. 15 Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R 2001 Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor‐dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA 98: 6800–6805.
16. 16 Sigmundsdottir H, Pan J, Debes GF, Alt C, Habtezion A, Soler D, Butcher EC 2007 DCs metabolize sunlight‐induced vitamin D3 to ‘program’ T cell attraction to the epidermal chemokine CCL27. Nat Immunol 8: 285–293.
17. 17 Koizumi T, Nakao Y, Matsui T, Nakagawa T, Matsuda S, Komoriya K, Kanai Y, Fujita T 1985 Effects of corticosteroid and 1,24R‐dihydroxy‐vitamin D3 administration on lymphoproliferation and autoimmune disease in MRL/MP‐lpr/lpr mice. Int Arch Allergy Appl Immunol 77: 396–404.
18. 18 Abe J, Nakamura K, Takita Y, Nakano T, Irie H, Nishii Y 1990 Prevention of immunological disorders in MRL/l mice by a new synthetic analogue of vitamin D3: 22‐oxa‐1 alpha,25‐dihydroxyvitamin D3. J Nutr Sci Vitaminol (Tokyo) 36: 21–31.
19. 19 Lemire JM, Ince A, Takashima M 1992 1,25‐Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity 12: 143–148.
20. 20 Lemire JM, Archer DC 1991 1,25‐dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 87: 1103–1107.
21. 21 Cantorna MT, Hayes CE, DeLuca HF 1996 1,25‐Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 93: 7861–7864.
22. 22 Mattner F, Smiroldo S, Galbiati F, Muller M, Di Lucia P, Poliani PL, Martino G, Panina‐Bordignon P, Adorini L 2000 Inhibition of Th1 development and treatment of chronic‐relapsing experimental allergic encephalomyelitis by a non‐hypercalcemic analogue of 1,25‐dihydroxyvitamin D 3. Eur J Immunol 30: 498–508.
23. 23 Larsson P, Mattsson L, Klareskog L, Johnsson C 1998 A vitamin D analogue (MC 1288) has immunomodulatory properties and suppresses collagen‐induced arthritis (CIA) without causing hypercalcaemia. Clin Exp Immunol 114: 277–283.
24. 24 Cantorna MT, Hayes CE, DeLuca HF 1998 1,25‐Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 128: 68–72.
25. 25 Cantorna MT, Munsick C, Bemiss C, Mahon BD 2000 1,25‐Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 130: 2648–2652.
26. 26 Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R 1994 Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 37: 552–558.
27. 27 Mathieu C, Waer M, Casteels K, Laureys J, Bouillon R 1995 Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25‐dihydroxyvitamin D3, KH1060. Endocrinology 136: 866–872.
28. 28 Gregori G, Giarratana N, Smiroldo S, Uskokovic M, Adorini L 2002 A 1α,25‐Dihydroxyvitamin D 3 analog enhances regulatory T cells and arrests autoimmune diabetes in NOD mice. Diabetes 51: 1367–1374.
29. 29 Giarratana N, Penna G, Amuchastegui S, Mariani R, Daniel KC, Adorini L 2004 A Vitamin D analog downregulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J Immunol 173: 2280–2287.
30. 30 Casteels K, Waer M, Laureys J, Valckx D, Depovere J, Bouillon R, Mathieu C 1998 Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin D3 analog and cyclosporine. Transplantation 65: 1225–1232.
31. 31 Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L 2001 Regulatory T cells induced by 1α,25‐Dihydroxyvitamin D 3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 167: 1945–1953.
32. 32 Amuchastegui S, Daniel KC, Adorini L 2005 Inhibition of acute and chronic allograft rejection in mouse models by BXL‐628, a nonhypercalcemic vitamin D receptor agonist. Transplantation 80: 81–87.
33. 33 Ma Y, Khalifa B, Yee YK, Lu J, Memezawa A, Savkur RS, Yamamoto Y, Chintalacharuvu SR, Yamaoka K, Stayrook KR, Bramlett KS, Zeng QQ, Chandrasekhar S, Yu XP, Linebarger JH, Iturria SJ, Burris TP, Kato S, Chin WW, Nagpal S 2006 Identification and characterization of noncalcemic, tissue‐selective, nonsecosteroidal vitamin D receptor modulators. J Clin Invest 116: 892–904.
34. 34 Steinman RM, Hemmi H 2006 Dendritic cells: Translating innate to adaptive immunity. Curr Top Microbiol Immunol 311: 17–58.
35. 35 Liu YJ 2005 IPC: Professional type 1 interferon‐producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23: 275–306.
36. 36 Steinman RM, Hawiger D, Nussenzweig MC 2003 Tolerogenic dendritic cells. Annu Rev Immunol 21: 685–711.
37. 37 Penna G, Amuchastegui S, Giarratana N, Daniel KC, Vulcano M, Sozzani S, Adorini L 2007 1,25‐Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol 178: 145–153.
38. 38 Li Q, Verma IM 2002 NF‐kappaB regulation in the immune system. Nat Rev Immunol 2: 725–734.
39. 39 Peleg S, Ismail A, Uskokovic MR, Avnur Z 2003 Evidence for tissue‐ and cell‐type selective activation of the vitamin D receptor by Ro‐26‐9228, a noncalcemic analog of vitamin D3. J Cell Biochem 88: 267–273.
40. 40 Hewison M, Freeman L, Hughes SV, Evans KN, Bland R, Eliopoulos AG, Kilby MD, Moss PA, Chakraverty R 2003 Differential regulation of vitamin D receptor and its ligand in human monocyte‐derived dendritic cells. J Immunol 170: 5382–5390.
41. 41 Cantorna MT, Hullett DA, Redaelli C, Brandt CR, Humpal‐Winter J, Sollinger HW, Deluca HF 1998 1,25‐Dihydroxyvitamin D3 prolongs graft survival without compromising host resistance to infection or bone mineral density. Transplantation 66: 828–831.
42. 42 Ochando JC, Homma C, Yang Y, Hidalgo A, Garin A, Tacke F, Angeli V, Li Y, Boros P, Ding Y, Jessberger R, Trinchieri G, Lira SA, Randolph GJ, Bromberg JS 2006 Alloantigen‐presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 7: 652–662.